Trial Profile
Effectiveness and safety of silodosin in the treatment of LUTS in patients with benign prostatic hyperplasia: a European phase IV clinical study (the Silodosin in Real-life Evaluation study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Silodosin (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Therapeutic Use
- Acronyms SIRE
- Sponsors Recordati
- 15 Apr 2014 Results presented at the 29th Congress of the European Association of Urology.
- 02 Jan 2013 Planned end date changed from 17 Nov 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 02 Jan 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01757769).